MYND Life Sciences Inc. Granted Management Cease Trade Order
MYND Life Sciences Inc. Granted Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31, 2022 (the "2022 Financial Statements") prior to the filing deadline of February 28, 2023 (the "Annual Filing Deadline"). As a result, the Company will not be able to file the 2022 Financial Statements, accompanying Management Discussion & Analysis and CEO and CFO certifications, and the Annual Information Form (collectively, the "2022 Annual Filings") prior to the Annual Filing Deadline as required under applicable Canadian securities laws. The Company anticipates filing the 2022 Financial Statements by March 31, 2023.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年3月1日)-MyND生命科學公司。本公司(CSE：MYND)(以下簡稱“MyND”或“本公司”)宣佈，其外聘核數師(“核數師”)已告知本公司，他們將無法在截止日期2023年2月28日(“年度提交截止日期”)之前完成本公司截至2022年10月31日止年度綜合財務報表(“2022年財務報表”)的編制工作。因此，根據適用的加拿大證券法的要求，公司將無法在年度申報截止日期之前提交2022年財務報表、隨附的管理層討論和分析以及CEO和CFO證書，以及年度資訊表(統稱為“2022年年度申報”)。該公司預計在2023年3月31日之前提交2022年財務報表。
The Company further announces that it has been granted a management cease trade order (MCTO) under National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Company. The MCTO will remain in effect until the Company has filed its audited statements and the Executive Director of the BCSC has revoked the order. The Company will be required to comply with the provisions of the alternative information guidelines as set out in NP 12-203 for so long as the MCTO remains in effect, including the issuance of bi-weekly default status reports by way of press releases.
本公司進一步宣佈，根據加拿大證券管理人(“NP12-203”)針對本公司某些內部人士實施的國家政策12-203，本公司已獲授予管理停止交易令(MCTO)。在本公司提交其經審計的報表且BCSC的執行董事已撤銷訂單之前，MCTO將繼續有效。只要MCTO仍然有效，本公司將被要求遵守NP 12-203中規定的替代資訊指南的規定，包括以新聞稿的方式發佈兩周一次的違約狀態報告。
The Company will make further announcements with respect to the status of the 2022 Annual Filings as and when appropriate.
公司將在適當的時候就2022年年報的狀況發佈進一步的公告。
ABOUT MYND LIFE SCIENCES INC.
關於我的生命科學公司。
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.
我的名字生命科學公司是一家專注於神經藥物和新藥開發、診斷和疫苗的醫用生物技術藥物研究和開發公司。我的名字正在開發新的生物實體(NBE)和新的化學實體(NCE)，並通過克服疾病的獨特分子概念將自己與其他(生物)製藥公司區分開來。該公司通過嚴格的科學和臨床試驗推動藥物開發，同時努力申請專利並保護其知識產權。
Contact:
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Phone: 780 965-0122
Web:
聯繫方式：
Lyle Oberg博士，醫學博士，首席執行官
電子郵件：ir@myndcerences.com
電話：780965-0122
網頁：
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問